The Productivity Pill: The Economics of Brain Drugs Moving Beyond Medicine

On August 5, 2026, the FDA approved Orzeyful, a new drug for narcolepsy, a condition that affects roughly 120,000 Americans. It works by improving wakefulness, attention and motivation — the same things any employer, student or soldier would happily pay to have more of. That's the real story here, not a narcolepsy drug, but the first real test of how far the line between treating an illness and enhancing a healthy brain can bend. Nobody is claiming Orzeyful will end up in a healthy person's medicine cabinet, but drugs built for one purpose have a track record of finding a second, far more lucrative one, and once a pill can sharpen focus in the sick, keeping it away from the well gets harder by the year. That is the shift worth watching: what it would mean for who can afford access, for turning ordinary tiredness into a diagnosis, for misuse, and for a definition of “normal” human performance that keeps sliding the moment “enhanced” goes on sale.

Orexin is the brain chemical that keeps people alert, and losing it is what causes narcolepsy. Restore it, and the clinical trial data doesn’t stop at wakefulness, as it was found that 58–72% of treated patients showed meaningful gains in attention by week 12, against 18–26% on placebo. Eventhough, that is not a drug that only fixes sleep, The effects extend beyond simply keeping patients awake, with clinical trials also finding meaningful improvements in sustained attention.

The honest caveat is that improving attention in someone who lacks orexin is not the same as improving it in someone who doesn’t. Nobody serious is claiming Orzeyful is a smart pill. But the pharmaceutical industry has been here before, and it didn’t stay inside the treatment lane. Modafinil was approved in 1998 for sleep disorders; by 2004, the manufacturer itself reported that 90% of prescriptions were for off-label uses. It migrated from patients to pilots to students to traders in under a decade, with no chemical redesign required, just a population that decided the label didn’t apply to them.

That is the pattern that matters here, more than any single molecule. Once a drug demonstrates it can move alertness and attention in one direction, the question of who else might want that effect stops being hypothetical. If a drug can restore wakefulness in someone with a neurological deficit, what exactly prevents a later, more targeted version from increasing it in someone who has no deficit at all?

This is where the economics stop being abstract, because attention, alertness and endurance are not soft traits, they are inputs, the same way capital and labor hours are inputs, and underinvestment in them shows up on a balance sheet. Fatigue alone is estimated to cost the US economy up to $411 billion a year in lost productivity, or roughly 2.28% of GDP, mostly through underperformance at the desk rather than absenteeism, people show up, but slower, duller, and more error-prone. That is not a rounding error. It is a number large enough that any intervention which credibly narrows it, even partially, has an addressable market defined by the size of the gap, not by the size of any single patient population.

That is precisely the market logic the pharmaceutical industry already knows how to exploit, and there is a live precedent sitting one shelf over from narcolepsy. Semaglutide was approved as a diabetes drug. Once its weight-loss effect became impossible to ignore, Novo Nordisk and Eli Lilly didn’t treat that as an inconvenient side effect, they built an entire second brand, Wegovy, around it, and the combined franchise now generates more than $48 billion a year in global sales, the overwhelming majority of it driven by a population that was never diabetic to begin with. The lesson isn’t about diabetes or obesity. It’s about what happens when a drug’s incidental effect turns out to be worth more, to more people, than the effect it was approved for. Cognitive gains attached to a narcolepsy drug are sitting in exactly that position right now.

Any industry where output scales with sustained focus. trading floors, exam halls, cockpits, hospitals, has always had an implicit incentive to extend both, by coffee if nothing else. Modafinil already made that incentive pharmaceutical, and its documented use among students, faculty and people in high-pressure jobs like trading confirms the appetite was never limited to the sick. The demand side isn’t speculative, and it doesn’t need marketing to exist. In one UK university survey, 9.9% of students reported using modafinil to study, compared with 3.3% for methylphenidate and 1.9% for dexamphetamine a real, self-selecting market that formed entirely without a company aiming a campaign at it. Militaries reached the same conclusion decades earlier: the US Air Force ran a formal “go-pill” program built around amphetamines for long-haul missions, and Western air forces are currently relying on modafinil to keep pilots alert through extended combat sorties. None of this needed an orexin drug to exist — it just proves the market was already there, running on inferior tools, waiting for something better than caffeine and cleaner than amphetamine.

Adding to that, Takeda already has two follow-on orexin drugs, TAK-360 and TAK-495, in its pipeline for other sleep-wake indications, and it isn’t alone, Lilly, Eisai and Alkermes are all racing toward the same receptor. Follow the semaglutide playbook forward: label expansion first, mass-market repositioning second. If even one of these next-generation molecules turns out to be safer and more targeted than modafinil, the addressable market stops being defined by a narcolepsy diagnosis and starts being defined by anyone willing to pay for an edge. That’s the moment “The Productivity Pill” stops being a metaphor and starts being a line item.

No employer currently requires staff to drink coffee, and none is likely to require a prescription stimulant either. However, formal requirements were never how this works, if a subset of traders, surgeons or analysts quietly extend their functional hours, the baseline expectation of what a “full day” produces shifts for everyone around them, without a single policy being written. Students already operate this way: once enough of a cohort uses modafinil during exam season, “everyone else” becomes the implicit competitive benchmark, not the well-rested version of yourself.

Militaries are the clearest case, because the incentive is institutional rather than individual from the start. The US Air Force’s go/no-go pill protocol wasn’t an individual pilot’s choice — it was written policy, coordinated through flight surgeons, authorizing stimulant use above a mission-length threshold. That is what an “enhancement” market looks like once an institution, not a person, decides sustained alertness is operationally necessary. Civilian labor markets don’t have that kind of formal machinery yet. But they have the same underlying pressure: once a competitive advantage exists and is legal, waiting for regulation to catch up has historically been the losing strategy, not the safe one.

This is the productivity arms-race problem, and it doesn’t require villains. Early adopters gain a real edge. Everyone else faces a choice between matching it or falling behind a rising baseline they didn’t set. If some people can safely sustain longer, sharper output, does everyone else eventually stop having a choice about whether to try?

Even inside its narrow, legitimate patient population, Orzeyful is already a case study in unequal access before it has sold a single dose: it will only be distributed through specialty pharmacy once DEA scheduling clears, meaning gated access, insurance friction and paperwork from day one, for a genuinely sick population. Extend that same distribution logic to a future enhancement market, and the people who get early legal access are, as with most emerging pharmaceuticals, the well-insured and the well-connected first. That is not a hypothetical inequality, it’s the default distribution model already in place.

Misuse follows the same well-worn track modafinil cut. A drug regulators already flag for its effect on the brain’s reward circuitry, sitting inside a specialty-pharmacy system, is a plausible candidate for the same slow off-label drift that took modafinil from a 1998 narcolepsy approval to a 90% off-label prescription rate within six years. Meanwhile, the same drug class is already advancing into trials for ADHD, which is itself a diagnosis whose boundaries have expanded considerably over the past few decades, which is a pattern worth watching, not because ADHD isn’t real, but because diagnostic categories have a documented history of growing to meet available treatments.

The deeper question is what happens to the definition of “normal” once enhancement is legal, safe and unevenly adopted. Today, being tired after eight hours of work is unremarkable. If a meaningful share of a competitive workforce is pharmacologically extending its functional hours, does an unenhanced eight-hour day start reading as underperformance rather than as simply human? Regulation hasn’t caught up with this question anywhere yet, the DEA’s current 90-day scheduling clock on Orzeyful is itself a live example of policy trying to draw a line around a drug’s abuse potential after approval, not before. Nobody has yet had to decide whether an employer can reward enhancement, whether a university can police it, or whether “healthy” and “optimized” are even the same category anymore.

Thus, none of this requires believing that Orzeyful itself will end up in a healthy person’s medicine cabinet. It almost certainly won’t, and the caution around that claim is deserved. What it requires believing is something narrower and harder to dismiss: that the pharmaceutical, economic and institutional machinery capable of turning a wakefulness deficit into a wakefulness market already exists, has done this before with modafinil, and is now several billion dollars deep into doing it again with a more precise tool.

The question worth sitting with isn’t whether a productivity pill will make people more productive. It’s what happens to an economy, and to the people who can’t or won’t take it once human performance itself becomes just another input that can be pharmaceutically optimized, priced and sold. Who gets to decide what “normal” performance even means, once “better than normal” is available for a price?

Bell, Jacob. “Takeda Approval Ushers in New Wave of Sleep Drugs.” BioPharma Dive, August 6, 2026. https://www.biopharmadive.com/news/takeda-fda-sleep-drug-approval-orexin-orzeyful-narcolepsy/827190/.

European Pharmaceutical Review. “Takeda’s Orzeyful Approved in US as First-in-Class Orexin Treatment for Narcolepsy Type 1.” August 2026.  https://www.europeanpharmaceuticalreview.com/takedas-orzeyful-approved-in-us-as-first-in-class-orexin-treatment-for-narcolepsy-type-1/2136170.article.

GoalBMI Wellness. “Semaglutide Statistics 2026: Ozempic & Wegovy Data, Clinical Outcomes & Market Trends.” Last updated July 2026. https://wellness.goalbmi.com/semaglutide-statistics-2026/.

Grossi, Giuliana. “FDA Approves First Orexin Agonist for Narcolepsy Type 1.” AJMC, August 21, 2026. https://www.ajmc.com/view/fda-approves-first-orexin-agonist-narcolepsy-type-1.

Hadar, Or. “The Pill Keeping Fighter Pilots Awake: How a Drug Helps Air Forces Fly Through Extreme Fatigue.” Ynetnews, March 7, 2026. https://www.ynetnews.com/health_science/article/bkczskytzg.

Kesta, Alexia, and Philip M. Newton. “Student Cognitive Enhancement with Non-Prescribed Modafinil: Is It Cheating?” medRxiv, preprint, posted March 4, 2024. https://doi.org/10.1101/2024.03.01.24303594.

Maslen, Hannah, Nadira Faulmüller, and Julian Savulescu. “Pharmacological Cognitive Enhancement—How Neuroscientific Research Could Advance Ethical Debate.” Frontiers in Systems Neuroscience 8 (2014): article 107. https://doi.org/10.3389/fnsys.2014.00107.

RAND Corporation. “Lack of Sleep Costing U.S. Economy Up to $411 Billion a Year.” News release, November 30, 2016. https://www.rand.org/news/press/2016/11/30.html.

Takeda Pharmaceutical Company Limited. “U.S. FDA Approves Takeda’s ORZEYFUL™ (Oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1.” News release, August 5, 2026. https://www.takeda.com/newsroom/newsreleases/2026/orzeyful-approved-narcolepsy/.

Taylor, Nick Paul. “Takeda Leads Wave of Orexin Drugs with Potential to Upend Narcolepsy Market.” BioSpace, August 19, 2026. https://www.biospace.com/business/takeda-leads-wave-of-orexin-drugs-with-potential-to-upend-narcolepsy-market.

Veit, Walter. “Cognitive Enhancement and the Threat of Inequality.” Journal of Cognitive Enhancement 2, no. 4 (2018): 404–410. https://doi.org/10.1007/s41465-018-0108-x.

Yannix, Joshua. “Modafinil as a Cognitive Enhancer.” Senior thesis, Vassar College, 2017. https://digitallibrary.vassar.edu/sites/default/files/202201/Modafinil_as_a_cognitive_enhancer_0.pdf.